Principia Biopharma Inc. (PRNB) and Its Rivals Financial Results Comparison

As Biotechnology company, Principia Biopharma Inc. (NASDAQ:PRNB) is competing with its competitors based on the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Insider and Institutional Ownership

91.1% of Principia Biopharma Inc.’s shares are owned by institutional investors. Comparatively, 50.88% of all Biotechnology’s companies shares are owned by institutional investors. 9.8% of Principia Biopharma Inc. shares are owned by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are owned by company insiders.

Profitability

On first table we have Principia Biopharma Inc. and its competitors’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Principia Biopharma Inc. -6.10% 0.00% 0.00%
Industry Average 1,464.25% 88.44% 21.62%

Valuation and Earnings

In next table we are comparing Principia Biopharma Inc. and its competitors’ gross revenue, net income and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Principia Biopharma Inc. 2.83M 46.37M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Recommendations

Table 3 shows summary of recent ratings for Principia Biopharma Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Principia Biopharma Inc. 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

The potential upside of the competitors is 173.20%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Principia Biopharma Inc. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Principia Biopharma Inc. -0.68% 14.53% 0% 0% 0% -15.25%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Principia Biopharma Inc. had bearish trend while Principia Biopharma Inc.’s peers had bullish trend.

Liquidity

Principia Biopharma Inc. has a Current Ratio of 6.1 and a Quick Ratio of 6.1. Competitively, Principia Biopharma Inc.’s competitors Current Ratio is 7.68 and has 7.52 Quick Ratio. Principia Biopharma Inc.’s competitors have better ability to pay short and long-term obligations than Principia Biopharma Inc.

Dividends

Principia Biopharma Inc. does not pay a dividend.

Summary

Principia Biopharma Inc.’s competitors show that they’re better in 4 of the 4 indicators compared to the company itself.

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.